On August 27, 2024, Zydus Lifesciences Limited and its subsidiaries received final approval from the US Food and Drug Administration (USFDA) to market Amantadine extended-release capsules in 68.5 mg strength, along with a tentative approval for the 137 mg strength. These capsules, equivalent to Gocovri®, are used to treat dyskinesia in Parkinson’s disease patients who …